381.4 ð ç« æ«éèš Summary
381.4.1 ð äžå¥è©±çžœçµ
Atypical parkinsonism = parkinsonism + additional features that distinguish from idiopathic PD + poor levodopa response often; classification â synucleinopathies (α-synuclein) â PD + DLB + MSA (multiple system atrophy) vs tauopathies (4R tau) â PSP (progressive supranuclear palsy) + CBD (corticobasal degeneration) + FTD-tau; MSA (multiple system atrophy) mean onset 55-65, survival 6-10 years; subtypes MSA-P (parkinsonian) vs MSA-C (cerebellar); severe autonomic failure early (orthostatic hypotension drop ⥠30/15 within 3 min + urinary incontinence/retention + sexual dysfunction + sweating abnormalities) + inspiratory stridor (laryngeal dystonia â characteristic + can be FATAL â CPAP life-saving) + REM sleep behavior disorder (common) + poor/early-failing levodopa response + pyramidal signs + bulbar dysfunction + cold/discolored hands; MSA pathology α-synuclein in glial cytoplasmic inclusions (GCIs â different from PD/DLB neuronal); MSA imaging â âhot cross bun signâ (pons cruciate hyperintensity on T2 â MSA-C) + putaminal atrophy with hyperintensity rim (MSA-P) + cerebellar atrophy (MSA-C); MIBG cardiac scintigraphy preserved in MSA (decreased in PD/DLB â distinguishing feature); treatment â no disease-modifying + supportive (midodrine/fludrocortisone/droxidopa for OH + catheterization + PEG dysphagia + CPAP for stridor LIFE-SAVING + PT/OT/speech) + levodopa trial may help motor briefly; PSP (progressive supranuclear palsy) mean onset 60-65, survival 5-8 years; hallmark vertical supranuclear gaze palsy (especially DOWNGAZE) + early falls (within 1 year onset â backward falls) + axial rigidity > limb + frontal cognitive impairment (apathy, dysexecutive) + pseudobulbar + dysphagia + dysarthria + apraxia of eyelid opening + square wave jerks + poor levodopa response; variants â Richardson syndrome (classic â gaze palsy + falls + cognitive) + PSP-P (parkinsonism predominant, mimics PD) + PSP-PGF (progressive gait freezing) + PSP-CBS (corticobasal syndrome) + PSP-SL (speech/language); PSP pathology 4R tau deposits + globose tangles + tufted astrocytes; PSP imaging â âhummingbird signâ (midbrain atrophy sagittal) + âMickey Mouse signâ (midbrain axial) + reduced midbrain : pons area ratio; no disease-modifying (multiple negative trials anti-tau gosuranemab/tilavonemab/BIIB092) + supportive + falls prevention + levodopa trial limited + botulinum for blepharospasm/dystonia + SSRIs pseudobulbar + amantadine sometimes; CBD (corticobasal degeneration) mean onset 60-70, survival 6-8 years; asymmetric parkinsonism + cortical features â alien limb phenomenon (involuntary movements feel ânot theirsâ, levitation, avoidant, intermanual conflict) + cortical sensory loss (astereognosis, agraphesthesia) + apraxia (ideomotor) + myoclonus + dystonia (often arm) + asymmetric limb rigidity + cognitive impairment + aphasia variants + poor levodopa response; CBS (corticobasal syndrome) clinical vs CBD pathological (CBS can be due to multiple pathologies â CBS-PSP, CBS-AD overlap); CBD pathology 4R tau + astrocytic plaques + ballooned neurons; CBD imaging â asymmetric perirolandic atrophy + DAT-scan reduced; no disease-modifying + supportive; DDx vertical gaze palsy â PSP (most common in elderly) + Whipple disease (oculomasticatory myorhythmia pathognomonic + cognitive + ceftriaxone + TMP-SMX) + Niemann-Pick C (lysosomal storage + miglustat) + Wilson disease + brainstem stroke + dorsal midbrain Parinaud (Sylvian aqueduct compression)ã
381.4.2 ð æ²»ç粟èŠ
- MSAïŒCPAP at night for stridor (LIFE-SAVING â tracheostomy if severe vocal fold paralysis later) + midodrine 5-10 mg TID + fludrocortisone 0.1-0.3 mg/d + droxidopa (Northera) for orthostatic hypotension + intermittent catheterization or alpha blocker for urinary + PEG for dysphagia + levodopa trial (may help briefly motor) + multidisciplinary PT/OT/speech therapy
- PSPïŒlevodopa trial (limited response) + amantadine sometimes + botulinum toxin for blepharospasm + dystonia + apraxia of eyelid opening + SSRIs + dextromethorphan-quinidine (Nuedexta) for pseudobulbar affect + falls prevention (PT, home modifications, gait aids) + multidisciplinary care
- CBDïŒlevodopa trial (rarely helps) + botulinum toxin for dystonia + myoclonus (clonazepam, levetiracetam, valproate) + speech therapy for apraxia + multidisciplinary
- disease-modifying â none for any; multiple anti-tau (PSP) + anti-α-synuclein (MSA) trials disappointing; ongoing research
381.4.3 ð¯ ç§é«åž«çèåæé
- Synucleinopathies vs tauopathies: synucleinopathies (α-synuclein) = PD + DLB + MSA vs tauopathies (4R tau) = PSP + CBD; pathology + clinical features differ
- MSA hallmarks: severe autonomic failure early (orthostatic + urinary + sexual) + inspiratory stridor (LIFE-THREATENING â CPAP life-saving!) + REM sleep behavior disorder + poor levodopa response + cerebellar (MSA-C) or parkinsonian (MSA-P) + pyramidal signs + cold hands
- MSA imaging: âhot cross bun signâ in pons on T2 (cruciate hyperintensity â MSA-C) + putaminal atrophy with hyperintensity rim (MSA-P) + cerebellar atrophy; MIBG-cardiac scintigraphy PRESERVED in MSA but DECREASED in PD/DLB (key distinguishing feature)
- PSP hallmarks: vertical supranuclear gaze palsy (especially DOWNGAZE â âdollâs eyeâ maneuver overcomes, suggesting supranuclear) + early falls (within 1 year â backward falls!) + axial rigidity > limb + frontal cognitive impairment + Richardson syndrome classic + variants (PSP-P, PSP-PGF, PSP-CBS, PSP-SL)
- PSP imaging: âhummingbird signâ on sagittal MRI (midbrain atrophy) + âMickey Mouse signâ on axial + reduced midbrain : pons area ratio
- CBD hallmarks: asymmetric parkinsonism + alien limb phenomenon + cortical sensory loss + apraxia + myoclonus + dystonia + cognitive impairment + aphasia variants; CBS clinical vs CBD pathological (CBS can be PSP/AD/CBD)
- PD vs atypical distinguishing: PD has rest tremor + asymmetric + good levodopa response + late falls vs atypical has poor levodopa + early falls + autonomic (MSA) or vertical gaze (PSP) or alien limb/cortical signs (CBD) or symmetric onset
- No disease-modifying therapy for any; anti-tau therapies for PSP disappointing (gosuranemab, tilavonemab, BIIB092 â all negative) + supportive management
- MSA stridor: CPAP at night LIFE-SAVING + tracheostomy for severe; vocal fold paralysis can develop
- DDx vertical gaze palsy: PSP (most common in elderly) + Whipple disease (oculomasticatory myorhythmia PATHOGNOMONIC + GI symptoms + ceftriaxone + TMP-SMX) + Niemann-Pick C (lysosomal storage + miglustat) + Wilson disease + brainstem stroke + dorsal midbrain Parinaud syndrome (Sylvian aqueduct compression â pinealoma, hydrocephalus)